Acta Haematologica · 2011 · 65 citations · 27 references
MedicineHematologyOncologyCancer ImmunologyChemotherapyHematologic OncologyCancer Survival AnalysisHematologic MalignanciesHematologic Malignancy TherapyLymphoid NeoplasmsLymphoid TumorsBone Marrow Involvement AssessmentLymphoid Neoplasm PrognosisLymphoma Bone Marrow InvolvementLymphoma Molecular ClassificationLymphoma Treatment ResponsePrognostic BiomarkersPrognostic Factors AnalysisRituximab-based Therapy
The aim of this study was to evaluate the impact of clinical variables and biologic features on response rate (RR), overall survival (OS) and progression-free survival (PFS) in 111 patients with de novo diffuse large B cell lymphoma (DLBCL). Fifty-three patients were treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) and 58 patients were treated with R-CHOP (rituximab + CHOP). The variables predictive of RR in the CHOP group were B symptoms, age, clinical stage, bone marrow involvement, bulky disease, International Prognostic Index (IPI) and Bcl-2; in the R-CHOP group, these variables were bulky disease, bone marrow involvement, IPI and Ki67 expression >80%. Multivariate analysis showed that in patients treated with CHOP, the independent prognostic factors associated with PFS were age, bulky disease, IPI and Bcl-2 and those associated with OS were performance status, clinical stage, IPI and bone marrow involvement. In contrast, in patients treated with R-CHOP, the variable shown by multivariate analysis to be an independent prognostic factor associated with PFS was bulky disease, whereas Ki67 expression >80% was associated with OS and PFS. Our data show that a high Ki67 expression and bulky disease could represent possible predictive factors of poor prognosis, which would help to identify a high-risk subgroup of newly diagnosed DLBCL.
27
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis et al. · Nature · 2000 · 10K citations
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp, David P. Harrington, J R Anderson et al. · 1993 · 3.5K citations
Medicine, Oncology, Chemotherapy +15
Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations
Medicine, Oncology, Chemotherapy +11